Evidence map›Paper›PMID 19198012›Full record

ArticlePest management science2009

Nanodisks protect amphotericin B from ultraviolet light and oxidation-induced damage.

Megan L Tufteland, Claude P Selitrennikoff, Robert O Ryan

Open access · greenAbstract readEvaluation Study
In one paragraph

Article in Pest management science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Megan L TuftelandChildren's Hospital Oakland Research Institute, Oakland, CA 94609, USA.
Claude P Selitrennikoff
Robert O Ryan
University of Colorado Denver · US

Funding

Leishmaniasis treatment: Macrophage scavenger receptorR01AI061354 · NIAID · CHILDREN'S HOSPITAL & RES CTR AT OAKLAND · PI RYAN, ROBERT O'MARA · 2006 to 2010
$1.9M
NIAID NIH HHS AI 61354NIAID NIH HHS R01 AI061354
6 · The paper itself

Abstract

backgroundMacrolide polyene antibiotics possess potent broad-spectrum antifungal properties. Use of these agents in the field or in controlled environments is impeded by their poor water solubility and susceptibility to oxidation- and/or light-induced degradation. While typically used for human disease therapy, there is potential to expand the utility of polyene macrolide antibiotics, such as amphotericin B, for control of fungal disease infestation in agricultural settings. Thus, the susceptibility of this antibiotic to exposure-induced activity loss was evaluated.

resultsIncubation of the prototype polyene amphotericin B (AMB) with phospholipid vesicles and apolipoprotein A-I results in the formation of nanoscale complexes, termed nanodisks (NDs), capable of solubilizing significant quantities of AMB. To evaluate whether AMB incorporation into NDs conferred protection against light- or oxidation-induced damage, yeast growth inhibition assays were conducted. Compared with AMB solubilized in detergent micelles, AMB incorporated into NDs was protected from damage caused by exposure to UV light as well as by KMnO(4)-induced oxidation. Furthermore, AMB-NDs inhibited growth of the turfgrass fungus Marasmius oreades Fr.

conclusionResults suggest that this water-soluble formulation of a natural, biodegradable, antifungal agent represents a potential cost-effective, non-toxic and environmentally friendly substitute for chemical agents currently employed to control a range of fungal infestations.

Indexed as

Ultraviolet RaysAmphotericin BChemistry, PharmaceuticalDrug StabilityFungiFungicides, IndustrialNanoparticlesOxidation-ReductionAmphotericin BFungicides, Industrial

Identifiers

PMID19198012
PMCPMC2893591
OpenAlexW2062349526

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.